Disc Medicine Q2 loss bigger than expected as costs increase

Disc Medicine

07/08/2025 13:38

Overview

Disc Medicine Q2 net loss of $55.2 mln missed analyst expectations

EPS for Q2 missed estimates, reflecting higher operating expenses

Company on track to submit NDA for bitopertin in EPP in Oct 2025

Outlook

Disc Medicine ends Q2 with $650 mln in cash, expected to fund operations into 2028

Result Drivers

CLINICAL TRIAL PROGRESSION - Increased R&D expenses driven by progression of bitopertin's clinical studies and DISC-0974 program-

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
Miss
-$55.25 mln
-$39.20 mln (8 Analysts)
Q2 EPS
Miss
-$1.58
-$1.16 (12 Analysts)
Q2 Operating Income
Miss
-$61.41 mln
-$41.40 mln (8 Analysts)
Q2 Operating Expenses
$61.41 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Disc Medicine Inc is $89.50, about 34.1% above its August 6 closing price of $59.00

Press Release: ID:nGNX82pT3H

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)